GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Last update: 04 Aug, 1:26AM

113.18

0.89 (0.79%)

  • 1D 0.79%
  • 5D -4.67%
  • 1M 0.79%
  • 6M -2.42%
  • YTD 23.18%
  • 1Y 42.01%
  • 5Y 69.56%
Previous Close 112.29
Open 112.26
Volume 5,016,408
Avg. Volume (3M) 7,757,511
Market Cap 140,787,990,528
Price / Earnings (TTM) 23.78
Price / Earnings (Forward) 14.14
Price / Sales 4.97
Price / Book 7.18
52 Weeks Range
72.43 (-36%) — 119.96 (5%)
Earnings Date 7 Aug 2025
TTM Dividend Yield 2.76%
Profit Margin 20.76%
Operating Margin (TTM) 38.49%
Diluted EPS (TTM) 4.76
Quarterly Revenue Growth (YOY) -0.30%
Quarterly Earnings Growth (YOY) 24.80%
Total Debt/Equity (MRQ) 130.79%
Current Ratio (MRQ) 1.37
Operating Cash Flow (TTM) 10.37 B
Levered Free Cash Flow (TTM) 9.99 B
Return on Assets (TTM) 12.14%
Return on Equity (TTM) 32.65%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Mixed
Drug Manufacturers - General (Global) Mixed Mixed
Stock Gilead Sciences, Inc. Bearish Bullish

AIStockmoo Score

-0.1
Analyst Consensus -0.5
Insider Activity -1.5
Price Volatility -0.5
Technical Moving Averages 2.5
Technical Oscillators -0.5
Average -0.10

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
GILD 141 B 2.76% 23.78 7.18
AMGN 159 B 3.13% 24.16 20.85
AZN 226 B 2.13% 29.27 5.54
SNY 118 B 4.58% 16.37 1.48
GRFS 6 B 1.73% 28.00 1.13
BIIB 19 B - 12.73 1.13

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.10%
% Held by Institutions 89.79%
52 Weeks Range
72.43 (-36%) — 119.96 (5%)
Price Target Range
98.00 (-13%) — 133.00 (17%)
High 133.00 (Needham, 17.51%) Buy
Median 119.50 (5.58%)
Low 98.00 (RBC Capital, -13.41%) Hold
Average 117.50 (3.82%)
Total 2 Buy, 2 Hold
Avg. Price @ Call 118.61
Firm Date Target Price Call Price @ Call
RBC Capital 08 Aug 2025 98.00 (-13.41%) Hold 119.41
Truist Securities 08 Aug 2025 127.00 (12.21%) Buy 119.41
UBS 08 Aug 2025 112.00 (-1.04%) Hold 119.41
Needham 25 Jul 2025 133.00 (17.51%) Buy 116.20

No data within this time range.

  • 3M
Date Type Details
26 Aug 2025 Announcement European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
21 Aug 2025 Announcement Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
20 Aug 2025 Announcement Gilead Sciences to Present at Upcoming Investor Conferences
07 Aug 2025 Announcement Gilead Sciences Announces Second Quarter 2025 Financial Results
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
25 Jul 2025 Announcement Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
24 Jul 2025 Announcement Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
14 Jul 2025 Announcement Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
09 Jul 2025 Announcement Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
25 Jun 2025 Announcement Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
18 Jun 2025 Announcement Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
18 Jun 2025 CNBC FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
01 Jun 2025 Announcement Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
31 May 2025 Announcement Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
Show more
TTM Dividend Yield 2.76%
5Y Average Dividend Yield 3.80%
Payout Ratio 65.13%
Expected Next Dividend Payment Sep 2025
Ex Date Announcement Date Payment Date Details
13 Jun 2025 22 Apr 2025 27 Jun 2025 0.79 Cash
14 Mar 2025 05 Feb 2025 28 Mar 2025 0.79 Cash
13 Dec 2024 30 Oct 2024 30 Dec 2024 0.77 Cash
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 Cash
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 Cash
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 Cash
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 Cash
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 Cash
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 Cash
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 Cash
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 Cash
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 Cash
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 Cash
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 Cash
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 Cash
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 Cash
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 Cash
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 Cash
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 Cash
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 Cash
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 Cash
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 Cash
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 Cash
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 Cash
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 Cash
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 Cash
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 Cash
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 Cash
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 Cash
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 Cash
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 Cash
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 Cash
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 Cash
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 Cash
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 Cash
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 Cash
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 Cash
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 Cash
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 Cash
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 Cash
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.58 2 1.40
2024 3.08 4 3.33
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria